Many patients when they start their cancer therapy get so ingrained in the cancer world that their oncologist just becomes their main point of contact, but we have to do a better job at letting the patients know that the PCP still is an integral part of their care, said Kelly Filchner, MSN, director at Fox Chase Cancer Center Partners.
Many patients when they start their cancer therapy get so ingrained in the cancer world that their oncologist just becomes their main point of contact, but we have to do a better job at letting the patients know that the PCP still is an integral part of their care, said Kelly Filchner, MSN, director at Fox Chase Cancer Center Partners.
Transcript
Ideally, how can primary care physicians be leveraged to improve coordination of care for cancer survivors?
I think the first thing is that in cancer care, we need to teach patients right from the beginning that their PCP is going to be involved. Many patients when they start their cancer therapy, they get so ingrained in the cancer world, and the oncologist just becomes their main point of contact that they forget that they actually have a PCP, and they want oncology to be fixing everything.
So, if they have diabetes, or they have hypertension, they want the oncologist to take care of those things, but really, their PCP should be doing that. So, I don't think sometimes we do a good job of letting the patients know that the PCP still is an integral part of their care.
How can this in turn affect cancer outcomes and non-cancer outcomes?
There's been a lot of studies looking at Medicare claims and seeing if patients who have cancer versus don't have cancer—how they get their follow up care. So, if somebody has a heart attack, and they also have a cancer diagnosis, are they still getting all the follow up care for the heart attack that somebody without cancer would. So, there's mixed reviews on some of these studies. Some plainly show that the patients who have cancer don't go to those follow ups as much as they should, versus patients who do not have cancer.
In the United Kingdom in particular, the reviews are different. They have a different kind of health system. It's not as fragmented as we have here in the United States. The PCP really drives the care. So, when they did similar studies, out of their databases, claims databases, basically in the UK, they didn't find that—they found that the patients actually got the care that they were supposed to.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More